anxiety | CARLAT PUBLISHING

Navigating the Digital Generation: Social Media & Mental Health

March 24, 2025

Joshua Feder, MD and Mara Goverman

In today's podcast, we explore the connection between social media, mental health, and today's youth.

Clinical Update

Update on Escitalopram

January 1, 2025

Mariel Zeccola, APRN, PhD

Mariel Zeccola, APRN, PhD. Nurse practitioner in private practice, Westport, CT.

Dr. Zeccola has no financial relationships with companies related to this material.

Where does escitalopram fit in the treatment of anxiety, depression, OCD, and other disorders of children and adolescents? We review the data and help you decide where to place escitalopram in your own practice.

Expert Q&A

Managing Treatment-Resistant Anxiety Disorders in Older Adults

January 1, 2025

Carmen Andreescu, MD

Carmen Andreescu, MD

Professor of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Dr. Andreescu has no financial relationships with companies related to this material.

Managing treatment-resistant anxiety in older adults requires a tailored approach. Dr. Andreescu explores the latest evidence on effective interventions for treatment-resistant anxiety, from medication strategies to lifestyle changes. Learn how chronic anxiety impacts aging, why standard treatments may fail, and how to optimize care for better long-term outcomes.

Expert Q&A

Identifying and Addressing Ageism in Psychiatric Practice

July 1, 2024

A. Mark Clarfield, MD, FRCPC

A. Mark Clarfield, MD, FRCPC.

Professor emeritus; Director, Centre for Global Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva; Chairman, National Council on Geriatrics Israel.

Dr. Clarfield has no financial relationships with companies related to this material.

Addressing ageism can improve a patient’s sense of self and independence. Dr. Clarfield provides practical suggestions.

Expert Q&A

Treatment Challenges in Atypical Parkinsonism

July 1, 2024

Alice Flaherty, MD, PhD

Alice Flaherty, MD, PhD.

Neurologist, Massachusetts General Hospital; associate professor of neurology and psychiatry, Harvard Medical School, Cambridge, MA.

Dr. Flaherty has no financial relationships with companies related to this material.

Patients with atypical parkinsonism are less responsive to levodopa, and psychiatric medications can exacerbate motor symptoms. Dr. Flaherty advises how to choose the right treatment in patients with parkinsonism accompanied by psychosis, apathy, anxiety, and depression.

Deprescribing Anti-anxiety Meds in Older Adults

March 25, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

All sorts of medications are prescribed for anxiety in older adults. Today, we look at when and how to discontinue them.

Clinical Update

Special Report: Refractory Anxiety Disorders Part 1: First-Line Treatments

March 1, 2024

Sarah Rivelli, MD.

Sarah K. Rivelli, MD, FACP, FAPA. System Director, Consult Liaison, Department of Psychiatry and Behavioral Medicine, Carilion Clinic. Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report; Assistant Professor, NYU Langone Department of Psychiatry; practicing psychiatrist, Winston-Salem, NC.

The authors have no financial relationships with companies related to this material.

When it comes to anxiety disorders, first-line options are more or less the same: SSRIs, SNRIs, and psychotherapy. But when those don’t work, a broader array of options opens up, and the choice is different for each disorder.

Hypnotic Depression Throwback

February 22, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

Here's a Throwback Thursday episode originally cast in March of 2021, where we're going to look at the question of whether adding a z hypnotic improves antidepressant response. And stay tuned to the very end where I'm going to update it with new research. We all know that when you sleep better, you feel better.

Clinical Update

Inpatient Use of Benzodiazepines for Patients With Substance Use Disorders

January 31, 2024

Audrey Abelleira, PharmD, BCPP

Audrey Abelleira, PharmD, BCPP. Clinical pharmacist practitioner, VA Connecticut Healthcare System; clinical instructor, Yale School of Medicine, New Haven, CT.

Dr. Abelleira has no financial relationships with companies related to this material.

Benzodiazepines are highly beneficial for managing anxiety and agitation in psychiatric inpatient settings, but we must be cautious about prescribing them to patients with substance use disorders (SUDs). Here we review strategies to reduce the risk of benzodiazepine misuse and discuss alternative medication options, including second-generation antipsychotics, antidepressants, gabapentin, and pregabalin.

Expert Q&A

Tolerability of Vortioxetine for Pediatric Anxiety and Depressive Disorders

January 1, 2024

Kathryn Martin, MD, MPH

Kathryn Martin, MD, MPH. Dr. Martin discloses that she owns shares in a variety of pharmaceutical companies. Relevant financial relationships listed for the author have been mitigated.

Vortioxetine has to be reasonably tolerated in children and teens, with manageable side effects, to have any chance of inclusion into treatment for anxiety or depression. This research update gives you the latest on whether vortioxetine might be a viable approach even before we have good efficacy studies.